Earlier pegcetacoplan preserves more retinal tissue in geographic atrophy

The GALE open-label extension analyzed up to 48 months of continuous pegcetacoplan treatment versus delayed treatment (24 months sham followed by 24 months of treatment) in eyes with geographic atrophy from OAKS and DERBY. The study reported that 48 months of continuous treatment reduced GA area growth rate by up to 24% versus projected sham, and eyes with nonsubfoveal GA in the early treatment group retained roughly three times more retinal tissue than those in the delayed treatment group (up to 3.16 mm2 versus 1.11 mm2). The study also reported reduced risk of progression to absolute scotoma at central 4 and 16 loci (32% and 43%, respectively), with safety data over 48 months consistent with prior OAKS and DERBY findings.

Most relevant for: Patients with nonsubfoveal or subfoveal geographic atrophy secondary to age-related macular degeneration being considered for pegcetacoplan therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.